Verified RAC-US Q&As - Pass Guarantee RAC-US Exam Dumps
Check the Free demo of our RAC-US Exam Dumps with 100 Questions
The Regulatory Affairs Certification (RAC) is a globally recognized certification program that aims to assess the knowledge and expertise of regulatory professionals in the pharmaceutical, medical device, and biotechnology industries. The RAC certification program is offered by the Regulatory Affairs Professionals Society (RAPS), which is a leading professional organization for regulatory affairs professionals. The RAC certification program is designed to demonstrate the proficiency of regulatory professionals in understanding and navigating the complex regulatory landscape in the healthcare industry.
To be eligible to take the RAPS RAC-US certification exam, candidates must have a minimum of three years of regulatory experience. RAC-US exam is offered twice a year, in the spring and fall, and is administered at testing centers throughout the United States. Candidates who pass the exam earn the prestigious RAPS RAC-US certification, which is recognized by employers, clients, and stakeholders as a mark of excellence in the regulatory profession.
NEW QUESTION # 15
According to ISO 14971, what is the FIRST step when developing a risk management plan for a medical device?
- A. Risk analysis
- B. Risk management
- C. Risk estimation
- D. Risk control
Answer: A
NEW QUESTION # 16
A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?
- A. Obtain regulatory documents and history and provide the information to R&D.
- B. Obtain competitor research and provide the information to the management team.
- C. Summarize regulatory documents and history and provide the information to the management team.
- D. Ask the trade association representative to provide an overview of the new product area to the marketing team.
Answer: C
NEW QUESTION # 17
Which of the following BEST describes the purpose of the ICH?
- A. To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions
- B. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions
- C. To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions
- D. To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions
Answer: B
NEW QUESTION # 18
Which of the following is the PRIMARY purpose of an audit report?
- A. To carry out a complete review of product applications
- B. To train sales representatives
- C. To define how to prepare new product submissions
- D. To document compliance history
Answer: D
NEW QUESTION # 19
A company receives multiple complaints regarding the text included on a recently launched product's label. What action should the regulatory affairs professional take FIRST?
- A. Notify the regulatory authority.
- B. Recommend an immediate product recall.
- C. Compare the approved text with the product label
- D. Inform the production team.
Answer: C
NEW QUESTION # 20
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?
- A. Inform upper management immediately.
- B. Contact the legal department and ask them how to proceed.
- C. Resubmit the entire package.
- D. Verify the procedure in the regulation for the corrections.
Answer: D
NEW QUESTION # 21
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is safe for arthritis and without side effects."
- B. "Product X is effective for the treatment of arthritis."
- C. "Product X is effective in all patients with arthritis."
- D. "Product X is a guaranteed cure for arthritis."
Answer: B
NEW QUESTION # 22
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent requirement applied?
- A. Physical processing and packaging
- B. Production of Intermediate(s)
- C. Introduction of the API starting material
- D. Isolation and purification
Answer: A
NEW QUESTION # 23
During a routine review of promotional materials for a product, a regulatory affairs professional discovers an off-label indication. Which of the following would be the FIRST follow-up action for the regulatory affairs professional to take?
- A. Allow doctors to use the product for the off-label indication.
- B. Request that doctors stop using the product for the off-label indication.
- C. Contact the marketing department to recall the product.
- D. Communicate with the sales department to stop using the promotional materials.
Answer: D
NEW QUESTION # 24
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?
- A. Negotiate with colleagues and the authority to find a better time.
- B. Arrange for an inspection without all intended personnel.
- C. Insist that key personnel be available for the inspection.
- D. Inform the authority that the time is not suitable and request a new time
Answer: A
NEW QUESTION # 25
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and early technical design
- B. Early technical design and product release
- C. Product release and validation
- D. Concept development and validation
Answer: A
NEW QUESTION # 26
A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?
- A. Educate patients and healthcare providers on how to use the product
- B. Label the product for use in appropriate populations.
- C. Promote off-label use to a carefully selected patient population.
- D. Delay product launch until required studies are completed.
Answer: C
NEW QUESTION # 27
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. Randomization scheme and codes
- B. Detailed CV of all investigators
- C. Protocol and protocol amendments
- D. List of lECs or lRBs
Answer: B
NEW QUESTION # 28
GHTF recommends that the medical device manufacturer define the scope of the clinical evaluation based on which of the following?
- A. Instructions for use
- B. Risk analysis
- C. Essential principles
- D. Product literature
Answer: B
NEW QUESTION # 29
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 500 patients for three months
- B. 100 patients for 12 months
- C. 3.000 total patient exposures
- D. 200 patients for nine months
Answer: B
NEW QUESTION # 30
At a recent scientific meeting, Company Y had two booths:
* At one booth, Company Y provided brochures on a completed Phase II study.
* In an adjacent booth, Company Y's sales professionals were promoting one of Company
Y's marketed products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company
Y requesting that Company Y stop this practice in the future and demanding a formal response to the letter. How should the regulatory affairs professional at Company Y BEST respond?
- A. Inform the legal department of the letter and discuss how to respond.
- B. Inform Company X that it has no right to send such a letter and do nothing further.
- C. Inform the local regulatory authority of the letter and discuss how to respond.
- D. Acknowledge receipt of the letter in a written response but do nothing further.
Answer: A
NEW QUESTION # 31
The requirements for document control are located in which of the following documents?
- A. ISO 13485
- B. WHO guidelines
- C. ICH guidelines
- D. IEC 60601
Answer: A
NEW QUESTION # 32
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The ISO technical committee in charge of the area
- B. The ISO national member body
- C. The country's regulatory authority
- D. The ISO Secretariat
Answer: B
NEW QUESTION # 33
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Clinical affairs
- B. Regulatory agency
- C. Quality improvement
- D. Quality assurance
Answer: D
NEW QUESTION # 34
......
Get professional help from our RAC-US Dumps PDF: https://www.torrentvalid.com/RAC-US-valid-braindumps-torrent.html
Clear your concepts with RAC-US Questions Before Attempting Real exam: https://drive.google.com/open?id=1CC10H89Iv0whD95MNdE3g_OUpIEaogf4